Cytosorbents Corporation CTSO
- Market cap
- $13.6M
- P/E
- 0.0×
Follow CTSO
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.11 | 3.30 | 6.45 | 3.49 | 3.60 | 3.88 | 1.03 | 0.91 | 0.70 | 0.60 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 6.90 | 7.05 | 14.95 | 8.82 | 11.74 | 11.68 | 4.33 | 4.59 | 1.59 | 1.61 |
High Price
|
|||
| 65 | 84 | 125 | 153 | 195 | 221 | 198 | 186 | 149 | 129 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 10 | 15 | 23 | 25 | 41 | 43 | 35 | 31 | 36 | 37 |
Revenue
|
|||
| 58.50% | 63.58% | 66.72% | 70.48% | 73.05% | 74.41% | 59.77% | 70.62% | 69.92% | 71.48% |
Gross Margin
|
|||
| (12) | (9) | (18) | (20) | (9) | (25) | (34) | (30) | (22) | (9) |
EBT
|
|||
| (126.81%) | (60.31%) | (79.23%) | (81.60%) | (21.86%) | (58.60%) | (97.74%) | (96.70%) | (62.96%) | (23.20%) |
EBT Margin
|
|||
| (12) | (8) | (17) | (19) | (8) | (25) | (33) | (29) | (21) | (8) |
Net Income
|
|||
| 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
Depreciation
|
|||
| 7.49 | 10.97 | 14.65 | 15.47 | 21.13 | 19.91 | 15.92 | 13.92 | 13.08 | 11.91 |
Revenue/Sh
|
|||
| (9.40) | (6.40) | (11.20) | (12.00) | (4.00) | (11.40) | (15.00) | (12.80) | (7.60) | (2.60) |
Earnings/Sh
|
|||
| (5.29) | (4.68) | (7.06) | (10.39) | (2.89) | (6.46) | (12.96) | (9.70) | (5.30) | (3.98) |
Cash Flow/Sh
|
|||
| (0.47) | (1.22) | (0.99) | (0.94) | (0.86) | (1.97) | (2.96) | (0.42) | (0.25) | (0.13) |
Capex/Sh
|
|||
| (5.76) | (5.89) | (8.05) | (11.33) | (3.76) | (8.43) | (15.92) | (10.12) | (5.55) | (4.11) |
Free CF/Sh
|
|||
| 1.05 | 7.43 | 11.03 | 2.12 | 40.81 | 28.86 | 16.24 | 10.52 | 4.08 | 1.90 |
Book Value/Sh
|
|||
| 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.75 | 0.60 | 0.55 | 0.25 | 0.38 | 0.21 | 0.11 | 0.08 | 0.07 | 0.05 |
PS Ratio
|
|||
| 5.37 | 0.88 | 0.73 | 1.82 | 0.20 | 0.15 | 0.11 | 0.10 | 0.22 | 0.34 |
PB Ratio
|
|||
| 0.72 | 0.11 | 0.00 | 0.36 | (1.34) | (0.68) | (0.38) | (0.22) | 0.30 | 0.40 |
EV/Sales
|
|||
| (0.94) | (0.21) | 0.00 | (0.49) | 7.53 | 1.60 | 0.38 | 0.30 | (0.71) | (1.17) |
EV/FCF
|
|||
| (7) | (6) | (11) | (17) | (6) | (14) | (28) | (22) | (14) | (12) |
Op' Cash Flow
|
|||
| (1) | (2) | (2) | (2) | (2) | (4) | (6) | (1) | (1) | 0 |
Capex
|
|||
| (7) | (8) | (12) | (18) | (7) | (18) | (35) | (23) | (15) | (13) |
FCF
|
|||
| 4 | 13 | 21 | 11 | 72 | 51 | 24 | 11 | 12 | 11 |
Working Cap'
|
|||
| 5 | 10 | 10 | 15 | 1 | 14 | 5 | 5 | 14 | 17 |
Total Debt
|
|||
| 0 | (7) | (12) | 3 | (70) | (38) | (17) | (9) | 6 | 10 |
Net Debt
|
|||
| 1 | 10 | 17 | 3 | 79 | 63 | 35 | 23 | 11 | 6 |
Sh' Equity
|
|||
| (112.31%) | (52.05%) | (59.04%) | (62.57%) | (13.36%) | (27.37%) | (42.96%) | (50.34%) | (41.30%) | (17.91%) |
ROA
|
|||
| (715.47%) | (209.74%) | (216.12%) | (190.11%) | (73.46%) | (58.59%) | (107.43%) | (138.73%) | (61.12%) | (56.48%) |
ROIC
|
|||
| (246.41%) | (151.66%) | (126.57%) | (189.32%) | (18.97%) | (34.64%) | (67.00%) | (99.38%) | (119.80%) | (96.39%) |
ROE
|
|||
Cytosorbents Corporation peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PETV PetVivo Holdings, Inc. | $12.9M | 0.0× | Compare |
| RBOT Vicarious Surgical Inc. | $14.3M | 0.0× | Compare |
| SINT SINTX TECHNOLOGIES, INC. | $12.5M | 0.0× | Compare |
| NMTC NeuroOne Medical Technologies Corporation | $12.1M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BMRA Biomerica, Inc. | $11.3M | 0.0× | Compare |
| IRIX IRIDEX Corporation | $11.1M | 0.0× | Compare |
| PMI Flag Ship Acquisition Corp | $11.1M | 0.2× | Compare |
| ALUR Allurion Technologies, Inc. | $16.7M | 0.0× | Compare |
Cytosorbents Corporation (CTSO) key facts
- Cytosorbents Corporation (CTSO) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024.
- As of September 25, 2026, CTSO traded at $4.38, a market capitalization of $13.6 million.
- Return on equity was −96.4% and debt-to-equity -22.96.
Cytosorbents Corporation (CTSO) Latest News
23 Sep
CytoSorbents has regained Nasdaq’s minimum bid price compliance, with a closing price at or above $1.00 for 10 straight trading days through Sept. 21, 2026, satisfying Rule 5550(a)(2) and Nasdaq closing the matter. The company plans to achieve full Nasdaq Capital Market listing compliance by Dec. 28, 2026, addressing the Market Value of Listed Securities requirement or pursuing alternatives. CEO Dr. Phillip Chan says management will press on with driving CytoSorb sales, reaching operating cash-flow breakeven in H2 2026, advancing DrugSorb-ATR toward FDA approval, and unlocking assets such as HemoDefend-BGA. The release also highlights CytoSorbents’ EU-approval of CytoSorb and ongoing DrugSorb-ATR development, including Breakthrough Device Designations, noting DrugSorb-ATR is investigational in the U.S. and Canada. Regaining Nasdaq compliance and pursuing additional listing milestones provide moderate near-term clarity and potential sentiment lift, but core business trajectory remains driven by sales growth and regulatory progress rather than a transformative event.
3 Sep
CytoSorbents announced real-world data showing CytoSorb significantly reduces severe bleeding in CABG patients on Ticagrelor. Positive real-world data on bleeding reduction supports higher CytoSorb adoption and revenue growth.
2 Sep
CytoSorbents announces real-world data showing CytoSorb reduces severe bleeding in CABG patients on Ticagrelor and updates on DrugSorb-ATR FDA pre-submission meetings. Positive real-world efficacy data plus FDA regulatory progress support higher product adoption and approval prospects.
17 Aug
CytoSorbents future value drivers support a $4.00 price target. Analyst price target highlights value drivers that may lift investor sentiment and valuation modestly.
13 Aug
Cytosorbents (CTSO) released its Q2 2026 earnings call transcript covering financial results and outlook. Quarterly earnings details may influence short-term sentiment without major strategic shifts.
7 Aug
CytoSorbents Corp (CTSO) nears breakeven in Q2 2026 earnings with strong performance. Nearing breakeven signals major financial progress that can shift company trajectory and investor sentiment.
Cytosorbents Corporation held its Q2 2026 earnings call, covering financial results, operational updates, and forward outlook for the company. Quarterly earnings call delivers financial and strategic updates that moderately shape near-term market views without altering long-term trajectory.
6 Aug
CytoSorbents reported second quarter 2026 financial results along with recent business highlights and regulatory updates. Quarterly financial results and regulatory updates provide metrics that may affect short-term market sentiment.
21 May
CytoSorbents Corporation reported first quarter financial and operating results. Quarterly results update key performance metrics that moderately shape near-term investor views.
14 May
Cytosorbents Corporation discussed Q1 2026 financial results and outlook during its earnings call. Earnings call delivers updated financial metrics and guidance with moderate effects on near-term sentiment.
CytoSorbents Corp (CTSO) Q1 2026 earnings call highlights navigating operational challenges through strategic initiatives amid mixed financial results. Earnings highlights reveal challenges offset by strategic moves, moderately impacting financial trajectory and investor sentiment.
13 May
CytoSorbents Corporation (CTSO) released the full transcript of its Q1 2026 earnings conference call, detailing quarterly financial results, operational updates, and forward-looking guidance. Q1 2026 earnings transcript reveals financial performance, strategic initiatives, and guidance that could significantly sway investor sentiment and stock trajectory.
CytoSorbents Corporation reported first quarter 2026 financial results, recent business highlights, and a regulatory update. Quarterly financial results, business highlights, and regulatory update moderately influence financial performance and investor sentiment.
6 Apr
CytoSorbents Corporation (CTSO) reported strong fourth quarter and full-year 2025 financial results. Strong Q4 and full-year 2025 results highlight robust financial performance poised to significantly enhance CTSO's market trajectory and investor sentiment.
26 Mar
Cytosorbents Corporation (CTSO) released Q4 2025 earnings call transcript detailing financial results, operational updates, and management guidance. Q4 earnings transcript discloses financial performance, strategic initiatives, and outlook that could significantly sway investor sentiment and stock trajectory.
Cytosorbents Corporation reported Q4 2025 financial results in earnings call, covering revenue growth, CytoSorb sales, pipeline updates, and 2026 guidance amid ongoing commercialization efforts. Q4 earnings disclosure includes key financial metrics, operational progress, and forward guidance that significantly shape investor sentiment and stock trajectory.
25 Mar
CytoSorbents Corp (CTSO) Q4 2025 earnings call highlights navigating growth amid regulatory challenges. Earnings highlights detail growth strategies and regulatory navigation, likely driving significant shifts in financial outlook and investor sentiment.
CytoSorbents Corporation (CTSO) released its Q4 earnings snapshot, reporting financial results for the quarter. Q4 earnings snapshot provides critical financial data that can significantly sway investor sentiment and stock performance.
CytoSorbents Corporation reported fourth quarter and full year 2025 financial results, including recent business highlights. Quarterly and annual financial results with business highlights directly shape investor sentiment, stock valuation, and strategic outlook.
19 Mar
CytoSorbents launches HotSwap™, renews partnership with Aferetica, and presents new clinical evidence at ISICEM 2026. HotSwap™ launch, Aferetica partnership renewal, and new clinical evidence at a major conference drive significant product expansion and validation for CTSO.
14 Feb
Analysts predict that Cytosorbents Corporation (NASDAQ:CTSO) will reach breakeven soon, driven by advancements in its product offerings and market positioning. The company is focusing on expanding its applications and enhancing its technology, which could lead to improved financial performance. Investors are optimistic about the potential for growth and profitability in the near future. The anticipated breakeven point indicates a moderately noticeable influence on the company's financial performance and market sentiment.
13 Jan
Cytosorbents Corporation's price target has been raised to $5.00 due to higher than expected gross margins. This adjustment reflects improved financial performance and market sentiment towards the company's products and operations. Higher than expected gross margins indicate significant improvements in financial performance that could positively influence investor sentiment and the company's trajectory.
12 Jan
CytoSorbents Corporation reported preliminary unaudited results for the fourth quarter and full year of 2025, highlighting significant growth in revenue and product sales. The company continues to expand its product offerings and market presence, focusing on innovative therapies for critical care and other medical applications. Management provided insights into ongoing clinical studies and strategic initiatives aimed at enhancing shareholder value. The results indicate a positive trajectory for the company as it navigates the evolving healthcare landscape. Significant growth in revenue and product sales, along with strategic initiatives, suggest a major positive shift in the company's trajectory.
17 Nov
CytoSorbents Corporation (CTSO) is experiencing high margin revenue growth, which supports a price target of $4.00. The company's financial performance is bolstered by its innovative products and expanding market presence, indicating a positive outlook for investors. High margin revenue growth and a supportive price target suggest significant positive shifts in the company's market position.
CytoSorbents Corporation will present at the Jefferies Global Healthcare Conference in London, showcasing its innovative blood purification technology. The event is expected to enhance visibility and engagement with potential investors and partners in the healthcare sector. Participation in a major healthcare conference can moderately influence investor sentiment and company visibility.
14 Nov
CytoSorbents Corporation (CTSO) reported record revenue growth in Q3 2025, highlighting significant advancements in its product offerings and strategic initiatives. The company emphasized its commitment to expanding market reach and enhancing operational efficiency, which contributed to the positive financial results. Key developments included new partnerships and increased demand for its innovative therapies, positioning CTSO for continued success in the competitive landscape. Record revenue growth and strategic initiatives indicate a significant positive shift in the company's market position and future performance.
13 Nov
Cytosorbents Corporation reported its Q3 2025 earnings, highlighting significant advancements in its product pipeline and financial performance. The company noted increased revenue driven by strong demand for its blood purification technologies. Management provided insights into ongoing clinical trials and strategic partnerships aimed at expanding market reach. The outlook for the upcoming quarters appears optimistic, with expectations for continued growth and innovation in therapeutic applications. The advancements in product pipeline and financial performance indicate a significant impact on future growth and market positioning.
CytoSorbents Corporation reported its Q3 earnings, highlighting significant growth in revenue and product sales. The company continues to expand its market presence with innovative therapies aimed at treating critical illnesses. Key financial metrics showed improvement, indicating a positive trajectory for the company. Management expressed optimism about future developments and ongoing partnerships that could enhance their product offerings and market reach. Significant growth in revenue and product sales indicates a strong potential for future performance and market positioning.
CytoSorbents Corporation reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational advancements. The company provided updates on its product pipeline and strategic initiatives aimed at enhancing market presence. Management expressed optimism about future prospects and ongoing collaborations, indicating a focus on expanding the use of their technology in critical care settings. Significant product advancements and strategic initiatives are expected to enhance market positioning and investor sentiment.
30 Oct
CytoSorbents Corporation will report its financial results for the third quarter of 2025, along with recent business highlights. The announcement is anticipated by investors as it may provide insights into the company's performance and strategic direction. The upcoming financial results could moderately influence investor sentiment and provide insights into the company's operational performance.